| Literature DB >> 29244214 |
Emmanouil Antalis1, Zacharoula Oikonomopoulou1, Christine Kottaridi2, Athanasios Kossyvakis3, Aris Spathis2, Maria Magkana2, Aikaterini Katsouli1, Vassileios Tsagris4, Vassiliki Papaevangelou4, Andreas Mentis3, Sotirios Tsiodras1.
Abstract
The current study aimed to describe the molecular epidemiology of mixed respiratory viral infections during consecutive winter seasons in a tertiary care hospital. Patients with symptoms of respiratory tract infection were evaluated during the 2009-2011 and 2013-15 winter seasons. A clinical microarray technique was used for viral detection. Clinical and epidemiological data were correlated with mixed viral detection and the need for hospitalization. In 332 out of 604 (54.4%) evaluated patients (17.6% children) a respiratory virus was identified. Mixed viral infections were diagnosed in 68/332 (20.5%) patients with virus detection (66.2% mixed Influenza-RSV infections). Mixed viral infections were more commonly detected in children (OR 3.7; 95%CI 1.9-5.6, P < 0.01) and patients with comorbidities. In logistic regression analyses, mixed viral infections were associated with younger age (mean age 30.4 years vs. 41.8 years, P ≤ 0.001) and increased rates of fever (OR: 2.7; 95%CI 1.04-7.2, P < 0.05) but no adverse outcomes or increased rates of hospitalization. High rates of mixed viral infections were noted during all winter seasons (especially Influenza and RSV) and were more common in younger patients. The clinical significance of mixed respiratory viral infection needs further elucidation.Entities:
Keywords: epidemiology; influenza; respiratory syncytial virus (RSV)
Mesh:
Year: 2018 PMID: 29244214 PMCID: PMC7167177 DOI: 10.1002/jmv.25006
Source DB: PubMed Journal: J Med Virol ISSN: 0146-6615 Impact factor: 2.327
Demographics of the study population
| Variables, | Any virus, | Influenza, |
| Mixed virus, (%) | Mixed |
|---|---|---|---|---|---|
| Female gender, | 169/332 (50.9) | 98/194 (50.5) | 70/142 (49.3) | 33/68 (48.5%) | 20/45 (44.4) |
| Age 0‐4 yrs, | 31/332 (9.3) | 5/194 (2.6) | 27/142 (19) | 10/68 (14.7) | 4/45 (8.9) |
| Age 5‐17 yrs, | 53/332 (16) | 27/194 (13.9) | 34/142 (23.9) | 15/68 (22.1) | 11/45 (24.4) |
| Age 18‐40 yrs, | 101/332 (30.4) | 65/194 (33.5) | 41/142 (28.9) | 23/68 (33.8) | 16/45 (35.6) |
| Age 41‐65 yrs, | 84/332 (25.3) | 56/194 (28.9) | 27/142 (19) | 14/68 (20.6) | 11/45 (24.4) |
| Age >65 yrs, | 63/332 (19) | 41/194 (21.1) | 13/142 (9.2) | 6/68 (8.8) | 3/45 (6.7) |
| Hospitalization, | 92/332 (27.7) | 62/194 (32) | 22/142 (15.5) | 9/68 (13.2) | 6/45 (13.3) |
| Any comorbidities, | 180/402 (44.8) | 127/402 (31.6) | 22/402 (5.5) | 10/402 (2.5) | 3/402 (0.7) |
| Age ≩18 yrs | 165/180 (91.7) | 114/127 (89.8) | 22/22 (100) | 10/10 (100) | 3/3 (100) |
| COPD, | 67/180 (37.2) | 50/127 (39.3) | 8/22 (36.4) | 5/10 (50) | 2/3 (66.7) |
| CVD, | 58/180 (32.2) | 43/127 (33.9) | 5/22 (22.7) | 4/10 (40) | 1/3 (33.3) |
| Diabetes, | 30/180 (16.7) | 23/127 (18.1) | 3/22 (13.6) | 2/10 (20) | 1/3 (33.3) |
| Malignancy, | 10/180 (5.6) | 6/127 (4.7) | 0/22 (0) | 0/10 (0) | 0/3 (0) |
| ESRD, | 3/180 (1.7) | 2/127 (1.6) | 0/22 (0) | 0/10 (0) | 0/3 (0) |
| Allergy, | 17/180 (9.4) | 13/127 (10.2) | 2/22 (9.1) | 1/10 (10) | 0/3 (0) |
| Smoking, | 69/180 (38.3) | 46/127 (36.2) | 9/22 (40.9) | 6/10 (60) | 3/3 (100) |
| Influenza vaccine, | 41/180 (22.8) | 27/127 (21.3) | 6/22 (27.3) | 3/10 (30) | 1/3 (33.3) |
| Hospitalization, | 76/180 (42.2) | 56/127 (44.1) | 10/22 (45.5) | 5/10 (50) | 3/3 (100) |
Patients with Influenza‐like illness but no virology data were excluded. For comorbidities data are shown only for patients with available data (n = 402). Statistical significance for comparisons between groups with positive results and the rest of the group are flagged with an asterisk.
COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; ESRD, end stage renal disease.
Statistically significant associations (P < 0.05) are flagged.
Prevalence of identified viruses in the total population and in adults and children for patients with available virology data
| Virus | Total population, | Adults, | Children, |
|---|---|---|---|
| Any virus (+) | 332/604, 55% (50.9‐59%) | 248/498, 49.8% (45.3‐54.3%) | 84/106, 79.2% (70.1‐86.3%) |
| Influenza, total | 194/604, 32.1% (28.4‐36%) | 162/498, 32.5% (28.5‐36.9%) | 32/106, 30.2% (21.9‐40%) |
| Influenza A, | 120/604, 19.9% (16.8‐23.3%) | 101/498, 20.3% (16.9‐24.1%) | 19/106, 17.9% (11.4‐26.8%) |
| Influenza B | 75/604, 12.4% (9.9‐15.4%) | 62/498, 12.4% (9.7‐15.7%) | 13/106, 12.3% (7‐20.4%) |
| RSV, total | 142/604, 23.5% (20.2‐27.1%) | 81/498, 16.3% (13.2‐19.9%) | 61/106, 57.5% (47.6‐67%) |
| RSV A | 78/604, 12.9% (10.4‐15.9%) | 40/498, 8% (5.9‐10.9%) | 38/106, 35.8% (26.9‐45.8%) |
| RSV B | 110/604, 18.2% (15.3‐21.6%) | 59/498, 11.8% (9.2‐15.1%) | 51/106, 48.1% (38.4‐58%) |
| Parainfluenza viruses | 18/604, 3% (1.8‐4.8%) | 17/498, 3.4% (2.1‐5.5%) | 1/106, 0.9% (0.05‐5.9%) |
| Rhinovirus | 16/604, 2.6% (1.6‐4.4%) | 12/498, 2.4% (1.3‐4.3%) | 4/106, 3.8% (1.2‐9.9%) |
| Human metapneumovirus | 13/604, 2.2% (1.2‐3.8%) | 7/498, 1.4% (0.6‐3%) | 6/106, 5.7% (2.3‐12.4%) |
| Adenovirus | 6/604, 1% (0.4‐2.3%) | 3/498, 0.6% (0.2‐1.9%) | 3/106, 2.8% (0.7‐8.7%) |
| Bocavirus | 2/604, 0.3% (0.1‐1.3%) | 0/498, 0% (0‐%) | 2/106, 1.9% (0.3‐7.3%) |
| Coronavirus | 1/604, 0.2% (0.0‐1.1%) | 1/498, 0.2% (0.01‐1.3%) | 0/106, 0% (0‐4.3%) |
| Echovirus | 1/604, 0.2% (0.01‐1.1%) | 1/498, 0.2% (0.01‐1.3%) | 0/106, 0% (0‐4.3%) |
| Mixed RSV and influenza | 45/604, 7.5% (5.5‐9.9%) | 30/498, 6% (4.2‐8.6) | 15/106, 14.25 (8.4‐22.6%) |
| Mixed viral infections | 68/604, 11.3% (8.9‐14.1%) | 43/498, 8.6% (6.4‐11.5%) | 25/106, 23.6% (16.1‐33%) |
N over total population in each category is depicted, followed by prevalence rate and 95%CI in brackets.
Denotes P < 0.05.
Variability in viral detection per season studied and comparison to national data regarding influenza surveillance available from the Hellenic Center for Disease Control and Prevention
| 2009‐10 | 2010‐11 | 2013‐14 | 2014‐15 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Onset | Peak | End | Onset | Peak | End | Onset | Peak | End | Onset | Peak | End | |
| Influenza season, week/year, national data | 48/09 | 04/10 | 15/10 | 52/10 | 05/11 | 13/11 | 52/13 | 09/14 | 16/14 | 51/14 | 09/15 | 20/15 |
| Study period, week/year | 48/09‐04/10 | 03/11‐11/11 | 47/13‐20/14 | 43/14‐13/15 | ||||||||
| National (N)/Study (S) data | National | Study | National | Study | National | Study | National | Study | ||||
| Influenza (+) in ILI | 56.4% | 43.6% | 55.2% | 23.6% | 30.7% | 16.5% | 39.9% | 39.1% | ||||
| Influenza A | 100% | 100% | 95.4% | 92% | 95.8% | 95.5% | 41% | 32.1% | ||||
| Influenza A (H1N1) pdm09 in total A | 99.8% | 100% | 98.9% | 95.7 | 79.4% | 100% | 12.5% | 14.3% | ||||
| Influenza A (H3N2) in total A | 0.2% | 0% | 1.1% | 4.3% | 20.6% | 0% | 86.7% | 85.7% | ||||
| Influenza B | 0% | 0% | 4.6% | 0.9% | 4.2% | 0.8% | 59% | 26.9% | ||||
| RSV (+) study data | 45/94 (47.9%) | 75/106 (70.8%) | 12/133 (9%) | 10/271 (3.7%) | ||||||||
| Mixed virus infection | 27/94 (28.7%) | 31/106 (29.2%) | 1/133 (0.8%) | 9/271 (3.3%) | ||||||||
| Mixed | 23/94 (24.5%) | 19/106 (17.9%) | 0/133 (0%) | 3/271 (1.1%) | ||||||||
RSV, respiratory syncytial virus.
Figure 1Variability of virus detection per collected samples (in %, one equals 100%) during the 2010‐11 season per week of study
Epidemiological characteristics of patients with mixed viral infections versus those with single viral infection
| Single virus, | Mixed virus, |
| |
|---|---|---|---|
| Age, mean ± SD in yrs | 41.8 ± 25.6 | 30.4 ± 23 | ≤0.001 |
| Child, | 59/264 (22.3) | 25/68 (36.8) | 0.01 |
| COPD, | 62/170 (36.5) | 5/10 (50) | 0.5 |
| Cardiovascular disease, | 54/170 (31.8) | 4/10 (40) | 0.7 |
| Diabetes, | 28/170 (16.5) | 2/10 (20) | 0.7 |
| Neoplastic disease, | 10/170 (5.9) | 0/10 (0) | 1 |
| History of allergic condition, | 16/170 (9.4) | 1/10 (10) | 1 |
| Chronic renal diseases, | 3/170 (1.8) | 0 (0) | 1 |
| Tobacco use, | 63/170 (37.1) | 6/10 (60) | 0.19 |
| Influenza vaccination, | 38/170 (22.4) | 3/10 (30) | 0.7 |
| Fever, | 217/264 (82.2) | 63/68 (92.6) | 0.039 |
| Hospitalization, | 83/264 (31.4) | 9/68 (13.2) | 0.002 |
Data for comorbidities were available only for 180 people of the study population. N over total population in each category is depicted.
COPD, chronic obstructive pulmonary disease.
Denotes P < 0.05.